Skip to main content
Full access
Clinical and Research Reports
Published Online: 30 November 2016

Initial Response to Transcranial Magnetic Stimulation Treatment for Depression Predicts Subsequent Response

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

This study provides support for the hypothesis that treatment response to an initial course of repetitive transcranial magnetic stimulation (rTMS) for depression predicts the magnitude of response to a subsequent course of rTMS in the setting of symptom relapse.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 179 - 182
PubMed: 27899052

History

Received: 5 October 2016
Revision received: 15 October 2016
Accepted: 19 October 2016
Published online: 30 November 2016
Published in print: Spring 2017

Keywords

  1. Depression
  2. Antidepressants

Authors

Details

Michael S. Kelly, B.A.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Albino J. Oliveira-Maia, M.D., M.P.H., Ph.D.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Margo Bernstein, B.A.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Adam P. Stern, M.D.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Daniel Z. Press, M.D.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Alvaro Pascual-Leone, M.D., Ph.D.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Aaron D. Boes, M.D., Ph.D.
From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).

Notes

Previously presented as a poster at the 2016 Annual Meeting of the Clinical TMS Society, May 14, 2016, Atlanta.
Send correspondence to Dr. Boes; email: [email protected]

Competing Interests

Dr. Pascual-Leone serves on the scientific advisory boards of Constant Therapy, Neosync, Neuroelectrics, Neuronix, Novavision, Nexstim, and Starlab Neuroscience; and he is listed as the inventor in issued patents and patent applications on the real-time integration of transcranial magnetic stimulation with electroencephalography) and magnetic resonance imaging. All other authors report no financial relationships with commercial interests.

Funding Information

Harvard Catalyst10.13039/100007299: UL1 RR025758
National Institute of Neurological Disorders and Stroke10.13039/100000065: R25NS065743-05
Funded by the Sidney R. Baer Jr. Foundation (4K12HD027748-24, NIH/NINDS R25NS065743-05) and Harvard Catalyst|The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758 TR001102 and financial contributions from Harvard University and its affiliated academic healthcare centers).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share